National Guideline Clearinghouse | Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer.

HERE ►  full-text and MORE: download the CCO guideline...
National Guideline Clearinghouse | Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer.


Program in Evidence-based Care ||  Cancer Care Ontario Web site

December 2, 2013

Guideline Title

Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer.

Bibliographic Source(s)

Winquist E, Cripps C, Agbassi C, Messersmith H, Head and Neck Cancer Disease Site Group. Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer. Toronto (ON): Cancer Care Ontario (CCO); 2011 Sep 30. Various p. (Evidence-based series; no. 5-12).  [63 references]

Guideline Status

This is the current release of the guideline.
This guideline updates a previous version: Cripps C, Winquist E, Stys-Norman D, Devries M, Gilbert R, Head and Neck Cancer Disease Site Group. Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer: guideline recommendations. Toronto (ON): Cancer Care Ontario (CCO); 2009 May 15. 32 p. (Evidence bases series; no. 5-12).
The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from reviewing and updating activities.
Please visit the Cancer Care Ontario Web site  for details on any new evidence that has emerged and implications to the guidelines.